Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.

Riccardo RicciMaurizio MartiniGloria RavegniniTonia CenciMassimo MilionePaola LanzaFrancesco PiercontiDonatella SantiniSabrina AngeliniAlberto BiondiFausto RosaSergio AlfieriGennaro ClementeRoberto PersianiAlessandra CassanoMaria A PantaleoLuigi M Larocca

Published in: Clinical epigenetics (2019)

A subset of KIT/PDGFRA-WT GISTs, including their largest pathogenetically characterized subgroup (i.e., SDH-deficient ones), is preferentially MGMT-methylated. This finding could foster a reappraisal of alkylating agents for treating malignant cases occurring among these overall chemorefractory tumors.

Keyphrases

dna methylation
wild type
randomized controlled trial
gene expression
metastatic colorectal cancer
phase iii
study protocol
open label